title: Synthesis and hypolipidemic and antiplatelet activities of alpha-asarone isomers in humans (in vitro), mice (in vivo), and rats (in vivo).
abstract: A series of alpha-asarone isomers was synthesized and investigated for their hypolipidemic and antiplatelet activity. Considering the hypolipidemic activity in rats at a dose of 80 mg/kg/day, some isomers were more potent than clofibrate at 150 mg/kg. Compound 3 was one of the most active agents elevating the HDL cholesterol level by 56% and lowering the LDL cholesterol level by 46.8% in rats after 7 days of administration. The activities of the platelet aggregation test in vitro were significant but lower than those of the reference substances (indomethacine and acetylsalicylic acid). In the pulmonary thromboembolic in vivo test in mice, two compounds (alpha-asarone (6) and compound 4) produced significant antithrombotic effects at 100 mg/kg, namely 44% and 52% protection against lung microembolia, respectively. alpha-Asarone derivatives form a new group of potential hypolipidemic and/or antithrombotic agents. The compounds 3, 4, and 6 may serve as lead substances whose structural modifications may result in original drugs.
authors.affiliation: Institute of Chemistry, University of Bialystok, J. Pilsudskiego 11/4, 15-443 Bialystok, Poland.
authors.forename: J
authors.initials: J
authors.lastname: Poplawski
authors.forename: B
authors.initials: B
authors.lastname: Lozowicka
authors.forename: A T
authors.initials: AT
authors.lastname: Dubis
authors.forename: B
authors.initials: B
authors.lastname: Lachowska
authors.forename: S
authors.initials: S
authors.lastname: Witkowski
authors.forename: D
authors.initials: D
authors.lastname: Siluk
authors.forename: J
authors.initials: J
authors.lastname: Petrusewicz
authors.forename: R
authors.initials: R
authors.lastname: Kaliszan
authors.forename: J
authors.initials: J
authors.lastname: Cybulski
authors.forename: M
authors.initials: M
authors.lastname: Strzałkowska
authors.forename: Z
authors.initials: Z
authors.lastname: Chilmonczyk
mesh_terms: D000081248:Allylbenzene Derivatives; D000818:Animals; D000840:Anisoles / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D005343:Fibrinolytic Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D006801:Humans; D000960:Hypolipidemic Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D066298:In Vitro Techniques; D008168:Lung / Q000098:blood supply; D008297:Male; D051379:Mice; D010974:Platelet Aggregation / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D013237:Stereoisomerism; D013329:Structure-Activity Relationship; D013923:Thromboembolism / Q000517:prevention & control
chemical_list: D000081248:Allylbenzene Derivatives; D000840:Anisoles; D005343:Fibrinolytic Agents; D000960:Hypolipidemic Agents; C012195:asarone